These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8956684)

  • 21. Plasma reduced haloperidol/haloperidol ratios in schizophrenic patients treated with high dosages of haloperidol.
    Chang WH; Shieh YS; Liu HC; Jann MW; Chien CP
    Eur Neuropsychopharmacol; 1994 Jun; 4(2):119-26. PubMed ID: 7919941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Haloperidol plasma levels and clinical response: a therapeutic window relationship.
    Van Putten T; Marder SR; Mintz J; Poland RE
    Am J Psychiatry; 1992 Apr; 149(4):500-5. PubMed ID: 1554036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations.
    Davidson M; Kahn RS; Knott P; Kaminsky R; Cooper M; DuMont K; Apter S; Davis KL
    Arch Gen Psychiatry; 1991 Oct; 48(10):910-3. PubMed ID: 1929760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An open trial of buspirone added to neuroleptics in schizophrenic patients.
    Goff DC; Midha KK; Brotman AW; McCormick S; Waites M; Amico ET
    J Clin Psychopharmacol; 1991 Jun; 11(3):193-7. PubMed ID: 2066458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma clozapine levels and clinical benefit.
    Greenberg WM
    J Clin Psychiatry; 1995 Nov; 56(11):535-6. PubMed ID: 7592511
    [No Abstract]   [Full Text] [Related]  

  • 26. Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder.
    Volavka J; Cooper TB; Czobor P; Meisner M
    Arch Gen Psychiatry; 1995 Oct; 52(10):837-45. PubMed ID: 7575103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting haloperidol treatment response in chronic schizophrenia.
    van Kammen DP; Kelley ME; Yao JK; Gilbertson MW; Gurklis JA; Inosaka T; Saito H; Peters JL; Sato M
    Psychiatry Res; 1996 Aug; 64(1):47-58. PubMed ID: 8888364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Somatosensory-evoked potential changes during haloperidol treatment of chronic schizophrenics.
    Saletu B; Saletu M; Itil T; Marasa J
    Biol Psychiatry; 1971; 3(4):299-307. PubMed ID: 5163816
    [No Abstract]   [Full Text] [Related]  

  • 29. Sulpiride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and plasma concentrations.
    Gerlach J; Behnke K; Heltberg J; Munk-Anderson E; Nielsen H
    Br J Psychiatry; 1985 Sep; 147():283-8. PubMed ID: 3904885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma levels of haloperidol and clinical response.
    Van Putten T; Marder SR; May PR; Poland RE; O'Brien RP
    Psychopharmacol Bull; 1985; 21(1):69-72. PubMed ID: 3920705
    [No Abstract]   [Full Text] [Related]  

  • 31. Total and free plasma neuroleptic levels in schizophrenic patients.
    Tang SW; Glaister J; Davidson L; Toth R; Jeffries JJ; Seeman P
    Psychiatry Res; 1984 Dec; 13(4):285-93. PubMed ID: 6596586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of chlorprothixene and haloperidol in acute schizophrenia.
    Marjerrison G; Bowman R; Keogh RP
    Can Psychiatr Assoc J; 1971 Dec; 16(6):533-6. PubMed ID: 4947173
    [No Abstract]   [Full Text] [Related]  

  • 33. Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients.
    Ko GN; Korpi ER; Kirch DG
    J Clin Psychopharmacol; 1989 Jun; 9(3):186-90. PubMed ID: 2661607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of significant pharmacokinetic interaction between haloperidol and grapefruit juice.
    Yasui N; Kondo T; Suzuki A; Otani K; Mihara K; Furukori H; Kaneko S; Inoue Y
    Int Clin Psychopharmacol; 1999 Mar; 14(2):113-8. PubMed ID: 10220126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Haloperidol blood levels during dosage reduction in chronic schizophrenic patients.
    Goldman Z; Ebstein RP; Lerer B; Zohar J; Hermoni M; Belmaker RH
    Neuropsychobiology; 1981; 7(6):281-4. PubMed ID: 7312145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low plasma reduced haloperidol/haloperidol ratios in Chinese patients.
    Chang WH; Chen TY; Lee CF; Hu WH; Yeh EK
    Biol Psychiatry; 1987 Nov; 22(11):1406-8. PubMed ID: 3663790
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment of chronic schizophrenia with cyproheptadine: a double-blind placebo-controlled study.
    Silver H; Blacker M; Weller MP; Lerer B
    Biol Psychiatry; 1991 Sep; 30(5):523-5. PubMed ID: 1932400
    [No Abstract]   [Full Text] [Related]  

  • 38. The Dose Reduction in Schizophrenia (DORIS) Study: a final report.
    Hirschowitz J; Hitzemann R; Piscani K; Burr G; Frecska E; Culliton D; Mann M; Curtis C
    Schizophr Res; 1997 Jan; 23(1):31-43. PubMed ID: 9050126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
    Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
    Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Haloperidol blood levels and clinical outcome: a meta-analysis of studies relevant to testing the therapeutic window hypothesis.
    de Oliveira IR; de Sena EP; Pereira EL; Miranda AM; de Oliveira NF; Ribeiro MG; de Castro-e-Silva E; Dardennes RM; Samuel-Lajeunesse B; Marcilio C
    J Clin Pharm Ther; 1996 Aug; 21(4):229-36. PubMed ID: 8933296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.